{"transactions":[{"id":904,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-02T20:59:28.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1778,"derivative":{"exercise_price":107.72,"expiration_date":"2036-09-01","underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0001159036-26-000117","document":"wk-form4_1788382766.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000115903626000117/wk-form4_1788382766.xml","form_type":"4"}},{"id":903,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-02T20:59:28.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":1161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the\ndate of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1161,"source":{"system":"sec-edgar","filing":"0001159036-26-000117","document":"wk-form4_1788382766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000115903626000117/wk-form4_1788382766.xml","form_type":"4"}},{"id":914594,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:29:43.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":33.2,"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-012182","document":"tm265471-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465926012182/tm265471-1_4seq1.xml","form_type":"4"}},{"id":914593,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:29:43.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.3,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-26-012182","document":"tm265471-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465926012182/tm265471-1_4seq1.xml","form_type":"4"}},{"id":914592,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:29:43.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3840,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":71.8,"underlying":"Common Stock","underlying_shares":3840},"source":{"system":"sec-edgar","filing":"0001104659-26-012182","document":"tm265471-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465926012182/tm265471-1_4seq1.xml","form_type":"4"}},{"id":914591,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:29:43.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.874,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-012182","document":"tm265471-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465926012182/tm265471-1_4seq1.xml","form_type":"4"}},{"id":914590,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T22:29:43.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":736,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012182","document":"tm265471-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465926012182/tm265471-1_4seq1.xml","form_type":"4"}},{"id":914589,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T22:29:43.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":1263,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012182","document":"tm265471-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465926012182/tm265471-1_4seq1.xml","form_type":"4"}},{"id":1119924,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:05:12.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":0.3874,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-015959","document":"form4-06062025_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000141588925015959/form4-06062025_040609.xml","form_type":"4"}},{"id":1485174,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:05:08.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders."}],"balance_after":60000,"derivative":{"exercise_price":3.32,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-016179","document":"form4-06102024_040602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000141588924016179/form4-06102024_040602.xml","form_type":"4"}},{"id":1716508,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-11T21:30:19.000Z","date":"2023-12-08","kind":"purchase","planned":false,"acquired":true,"shares":7363,"price":1.79,"value":13179.77,"ownership":{"direct":false,"nature":"By Spouse"},"balance_after":7363,"source":{"system":"sec-edgar","filing":"0001415889-23-016186","document":"form4-12112023_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000141588923016186/form4-12112023_041201.xml","form_type":"4"}},{"id":1716507,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-11T21:30:19.000Z","date":"2023-12-08","kind":"purchase","planned":false,"acquired":true,"shares":637,"price":1.82,"value":1159.34,"ownership":{"direct":true},"balance_after":12637,"source":{"system":"sec-edgar","filing":"0001415889-23-016186","document":"form4-12112023_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000141588923016186/form4-12112023_041201.xml","form_type":"4"}},{"id":1720246,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-06T21:30:13.000Z","date":"2023-12-04","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":1.5,"value":18000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001415889-23-015929","document":"form4-12062023_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000141588923015929/form4-12062023_041201.xml","form_type":"4"}},{"id":1859106,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:15:05.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":4.83,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009604","document":"form4-06122023_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000141588923009604/form4-06122023_040601.xml","form_type":"4"}},{"id":1990644,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-02-27T23:08:34.000Z","date":"2023-02-24","kind":"sale","acquired":false,"shares":10385,"price":0.1274,"value":1323.049,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1273 to $0.1274, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-026139","document":"tm237991-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465923026139/tm237991-1_4seq1.xml","form_type":"4"}},{"id":2038727,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2023-02-02T02:40:03.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-23-009464","document":"tm235103-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465923009464/tm235103-3_4seq1.xml","form_type":"4"}},{"id":2038726,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-02-02T02:40:03.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":3878,"price":0.25,"value":969.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the reporting person."}],"balance_after":10385,"source":{"system":"sec-edgar","filing":"0001104659-23-009464","document":"tm235103-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465923009464/tm235103-3_4seq1.xml","form_type":"4"}},{"id":2038725,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-02-02T02:40:03.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":14263,"source":{"system":"sec-edgar","filing":"0001104659-23-009464","document":"tm235103-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000110465923009464/tm235103-3_4seq1.xml","form_type":"4"}},{"id":2187112,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-12T19:06:56.000Z","date":"2022-08-09","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on August 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on August 9, 2022."}],"balance_after":37500,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001709401-22-000016","document":"wf-form4_166033119872009.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000170940122000016/wf-form4_166033119872009.xml","form_type":"4"}},{"id":2187111,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-08-12T19:06:56.000Z","date":"2022-08-10","kind":"sale","acquired":false,"shares":5737,"price":0.8,"value":4589.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the reporting person."}],"balance_after":6763,"source":{"system":"sec-edgar","filing":"0001709401-22-000016","document":"wf-form4_166033119872009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000170940122000016/wf-form4_166033119872009.xml","form_type":"4"}},{"id":2187110,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-08-12T19:06:56.000Z","date":"2022-08-09","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001709401-22-000016","document":"wf-form4_166033119872009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000170940122000016/wf-form4_166033119872009.xml","form_type":"4"}},{"id":2205512,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-19T20:07:15.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":38400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 15, 2022. The shares underlying the option vest over three years, with 1/36 of the shares vesting at the end of each successive month following July 15, 2022."}],"balance_after":38400,"derivative":{"exercise_price":7.18,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":38400},"source":{"system":"sec-edgar","filing":"0001415889-22-007754","document":"form4-07192022_010704.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000141588922007754/form4-07192022_010704.xml","form_type":"4"}},{"id":2419490,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-02T02:19:53.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-22-000695","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000117911022000695/edgar.xml","form_type":"4"}},{"id":2419489,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-02T02:19:53.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter."}],"balance_after":125000,"derivative":{"exercise_price":6.75,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001179110-22-000695","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000117911022000695/edgar.xml","form_type":"4"}},{"id":2583882,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-02T00:12:45.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock units will vest in four equal annual installments beginning on August 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock units will vest in four equal annual installments beginning on August 9, 2022."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179110-21-008515","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000117911021008515/edgar.xml","form_type":"4"}},{"id":2583881,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-02T00:12:45.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on August 9, 2022, then in 12 equal quarterly installments thereafter."}],"balance_after":150000,"derivative":{"exercise_price":21.72,"expiration_date":"2031-08-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001179110-21-008515","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000117911021008515/edgar.xml","form_type":"4"}}]}